西藏城投(600773.SH):擬向北方集團申請續借委託貸款暨關聯交易
格隆匯 8 月 14日丨西藏城投(600773.SH)公佈,公司第八屆董事會第十八次(定期)會議決議,審議通過《關於公司向上海北方企業(集團)有限公司申請續借委託貸款暨關聯交易的議案》
為滿足公司經營發展的需要,補充公司流動資金,公司已於2017年向上海北方企業(集團)有限公司(“北方集團”)申請委託貸款,額度為15億元,借款期限為三年,借款利率為基準利率上浮5%,公司可在借款期限內根據資金情況在約定額度內提前歸還和續借。該事項已經公司第七屆董事會第二十四次會議以及公司2017年第三次臨時股東大會審議通過。現擬在該筆委託貸款到期後,續借三年,借款利率不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.